Hours to Minutes – How Medivir Accelerated Drug Discovery Data Analysis
D360の詳細はこちら
The discovery arm of Medivir sought an updated informatics infrastructure to improve the efficiency and flexibility of its data analysis and reporting. Existing in-house tools weren’t flexible and required team members to manipulate the data themselves in spreadsheet software before performing analyses; they then built reports manually in presentation software. The end goal was to reduce the time burden and error risk of manual data manipulations, while making it easier to manage data, access updates, and maintain project data tables. In addition, the scientists requested greater choice in analysis and reporting workflows.
The new informatics solution would have to be flexible enough to support a heterogeneous user group including biologists and computational, analytical, and medicinal chemists. It should support their existing data sources and analysis and reporting tools. While it should also be scalable and be quickly deployable to minimize disruption to workflows.
The discovery team eventually selected D360 as its new discovery data environment. In addition to supporting the team’s existing data sources and analysis tools, D360 provided a user-friendly interface for fast queries, analyses, and one-click reporting based on the latest data – across data sources. This meant scientists now had direct access to the data. Using D360, Medivir scientists also could now perform analyses with much less effort than before. For example, using built in chemistry intelligence for better understanding structure-activity relationships (SAR).
Within six weeks, Certara deployment specialists had installed, configured, and trained the discovery team on the use of D360. In a staggered roll out D360 was first deployed to 10 users, who rigorously tested the data handling capabilities and use-cases of the platform, and then rolled out to the rest of the team. The system connected team members across disciplines to all appropriate databases and enabled seamless data delivery to their preferred analysis tools without the need for manual manipulations.
- Time Savings: On-demand access to current, analysis- and report-ready data views accelerated data manipulation and opened new avenues of scientific exploration.
- Streamlined Workflow: An easy-to-use environment seamlessly connected data queries, analysis, and reporting.
- Flexibility & Collaboration: Teams could explore new ideas as they occurred by following a trail of evidence through multiple data sources, and easily share results with colleagues.
- Better Decision-Making: Bring together biological assay, drug metabolism, and PK data for a holistic view of a compound and easily combine data to make first-in-man dosing predictions.
Fast return on investment in the form of time-savings for scientific and IT staff, as well as accelerated decision-making. Analyses that once required hours was done in just a few minutes and saved results could be updated with new data almost instantly. Further, D360 freed IT resources from the burden of developing and maintaining in-house tools. And ultimately, direct access to the latest data ensured research decisions were informed by the most recent and complete information.
D360™（ディー・スリーシックスティ）は製薬業界を代表する科学データ専用のインフォマティクスプラットフォームです。現在、低分子化合物や生物学的製剤の創薬研究に携わる世界各国の6,000名を超える研究者に活用されています。従来であればIT部門の支援無しでは難しかった各データに対するアクセスを研究者主導で簡単に進めることができるだけでなく、解析や可視化も同一環境上で即座に実施することができます。D360を導入することで、様々なデータソースから必要なデータを集約する作業に振り向けていた時間や労力を本来の自身の専門性を活かしたデータの理解に集中させることが可能となります。To learn more, visit www.certara.com/d360.
